Supernus Pharmaceuticals (SUPN) EBITDA (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has reported EBITDA for 16 consecutive years, with -$58.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 577.42% year-over-year to -$58.0 million in Q2 2026; TTM through Jun 2026 was -$110.0 million, a 271.5% decrease from a year earlier, with the FY2025 full-year figure at -$62.3 million, down 176.27% from the prior year.
• EBITDA was -$58.0 million for Q2 2026 at Supernus Pharmaceuticals, down from -$3.9 million in the prior quarter.
• Over five years, EBITDA peaked at $40.8 million in Q3 2024 and troughed at -$60.2 million in Q3 2025.
• A 5-year average of $133823.5 and a median of $2.0 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 2249.1% in 2024 and sank 577.42% in 2026, its largest moves.
• Over 5 years, EBITDA stood at $34.3 million in 2022, then slumped by 102.9% to -$996000.0 in 2023, then soared by 2249.1% to $21.4 million in 2024, then tumbled by 118.39% to -$3.9 million in 2025, then slumped by 1372.26% to -$58.0 million in 2026.
• The last three EBITDA figures came in at -$58.0 million (Q2 2026), -$3.9 million (Q4 2025), and -$60.2 million (Q3 2025), per Business Quant data.